Fitzgerald Joseph Michael's Form 4 filing
Boston Scientific Corp (BSX) · filed Jun 4, 2025
- Accession no.
- 0001225208-25-005721
- Filed
- Jun 4, 2025
- Trade date
- Jun 4, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.80M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fitzgerald Joseph MichaelCIK 0001484186 | Officer (EVP & Group Pres, Cardiology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | Common Stock | MOption exerciseAcquired | +56,372 | $26.15 | +$1,474,127.8 | 234,714 | Direct | |
| Jun 4, 2025 | Common Stock | SSaleDisposed | −56,372 | $102.88F2 | −$5,799,551.36 | 178,342 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | Common Stock | MOption exerciseDisposed | −56,372 | $0.00 | $0 | 250,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.46 to $103.42, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.